Virtual lecture will be available soon.
Pediatricians, family physicians, oncologists, pediatric hematologists-oncologists, physician assistants, nurse practitioners, nurses, and oncology social workers at the intermediate and advanced levels involved in the care of patients with hematologic malignancies.
At the conclusion of this program, participants will be able to:
- Describe childhood blood cancers, including ALL, AML, and rare lymphomas such as Burkitt.
- Identify signs and symptoms of childhood blood cancer and diagnostic tests.
- Assess appropriate referral to a pediatric hematologist-oncologist and patient care during and post-cancer treatment.
- Explain treatments, including the role of clinical trials, and management of short- and long-term side effects
Susan R. Rheingold, MD
Medical Director, Oncology Outpatient Clinic
Cancer Center at Children's Hospital
Bradley J. Dyer, MD, FAAP
All Star Pediatrics
Continuing Education Information
This webcast is approved for 1.0 prescribed credit hours by the American Academy of Family Physicians (AAFP).
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under provider number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.
The Leukemia & Lymphoma Society (LLS), provider number 1105, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org Approved Continuing Education Program (ACE). Approval Period: 12/10/2017 to 12/10/2020. LLS maintains responsibility for the program. Social workers should contact their regulatory board to determine course approval. Social workers will receive 1.0 CE contact hour.
LLS is recognized by the New York State Education Departments State Board for Social Work as an approved provider of continuing education for licensed social workers #0117. LLS maintains responsibility for the program. Social workers will receive 1.0 clinical CE contact hour for this activity.
This program is provided by The Leukemia & Lymphoma Society (LLS) and Clinical Directors Network, Inc. (CDN)